JenaValve Hires Matt Bacso as Finance Chief

JenaValve, developer and manufacturer of the Trilogy transcatheter heart valve (THV) system, has appointed Matt Bacso as its new chief financial officer (CFO), effective June 8.

Bacso will lead the company’s financial organization and capital markets as it advances U.S. commercial launch of the Trilogy system for high risk, symptomatic, severe aortic regurgitation (ssAR). JenaValve believes his appointment will strengthen its executive leadership team during a crucial time of growth and U.S. commercial expansion.

Basco boasts over 15 years of investor relations, strategic finance, and business operations experience in the medical technology industry. He was most recently VP of investor relations and business operations at Procept BioRobotics, where he led investor communications, enterprise-wide financial strategy, and commercial planning as the company scaled from less than $30 million to about $400 million in revenue.

Before Procept BioRobotics, Bacso was managing director at Gilmartin Goup, a healthcare-focused strategic advisory firm, where he advised medical device executives on capital markets strategy and investor communications, including serving as a strategic advisor to JenaValve. He also previously worked in equity research at Piper Sandler and William Blair.

Last month, JenaValve appointed Edward (Ed) Sarnowski as its new chief technology officer. Sarnowski was most recently VP of R&D for TAVR and Congenital and subsequently VP of R&D, Mitral & Tricuspid at Medtronic Structural Heart.

Comments from JenaValve

John Kilcoyne, CEO: “Matt’s appointment is a significant addition to our executive team as JenaValve enters this next phase. Having previously worked with Matt, I have seen firsthand the depth of his financial expertise, his leadership within the medtech space, and his ability to communicate complex stories to investors with clarity and conviction. His knowledge of JenaValve, our mission, and the enormous opportunity in the AR space means he arrives ready to contribute from day one. I look forward to partnering with him as we build the financial foundation to support our commercial expansion and ongoing clinical programs.”

Matt Bacso, new CFO: “I am thrilled to join JenaValve as chief financial officer. Having had the opportunity to follow JenaValve’s journey closely, I have long believed in the transformative potential of the Trilogy System for patients with aortic regurgitation. As part of the leadership team advancing this mission, the opportunity ahead is both meaningful and significant. I look forward to working alongside this talented team to continue to build the foundation for JenaValve’s long-term growth.”